For example, microenvironmental disruption of the CLL niche potentiates the antitumour activity of Ibrutinib, and targeting stromal PKC-β in B-cell lymphomas enhances toxicity to common therapies [120,125]. The gene discussed is PRKCB; the disease is B-cell non-Hodgkin lymphoma.